Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

Nature Genetics

Volumn 42, Issue 8, 2010, Pages 722-726

  Ernst, Thomas ^a,c   Chase, Andrew J ^a,b   Score, Joannah ^a,b   Hidalgo Curtis, Claire E ^a,b   Bryant, Catherine ^a,b   Jones, Amy V ^a,b   Waghorn, Katherine ^a,b   Zoi, Katerina ^d   Ross, Fiona M ^a,b   Reiter, Andreas ^e   Hochhaus, Andreas ^c   Drexler, Hans G ^f   Duncombe, Andrew ^g   Cervantes, Francisco ^h   Oscier, David ⁱ   Boultwood, Jacqueline ^j   Grand, Francis H ^a,b   Cross, Nicholas C P ^a,b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b WESSEX REGIONAL GENETICS LABORATORY   (United Kingdom)

^c JENA UNIVERSITY HOSPITAL   (Germany)

^d BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f LEIBNIZ INSTITUTE DSMZ GERMAN COLLECTION OF MICROORGANISMS AND CELL CULTURES   (Germany)

^g SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^h UNIVERSITY OF BARCELONA   (Spain)

ⁱ ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^j JOHN RADCLIFFE HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE METHYLTRANSFERASE; POLYCOMB REPRESSIVE COMPLEX 2; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENICITY; CHROMOSOME 7Q; EPIGENETICS; EPITHELIUM TUMOR; GENE MUTATION; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCREENING; STEM CELL; TUMOR DIFFERENTIATION; TUMOR SUPPRESSOR GENE; UNIPARENTAL DISOMY;

CELL DIFFERENTIATION; DNA-BINDING PROTEINS; FEMALE; GENES, REGULATOR; GENES, TUMOR SUPPRESSOR; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; LYSINE; MALE; PROTEINS; TRANSCRIPTION FACTORS;

EID: 77955085750     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.621     Document Type: Article

References (39)

1. Heim, S. & Mitelman, F. Cancer Cytogenetics (Wiley Blackwell, 2009).
2. Grand, F.H. et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 113, 6182-6192 (2009).
3. Gondek, L.P. et al. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 111, 1534-1542 (2008).
4. Heinrichs, S. et al. Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia 23, 1605-1613 (2009).
5. Gupta, M. et al. Novel regions of acquired uniparental disomy discovered in acute myeloid leukemia. Genes Chromosom. Cancer 47, 729-739 (2008).
6. Raghavan, M., Gupta, M., Molloy, G., Chaplin, T. & Young, B.D. Mitotic recombination in haematological malignancy. Adv. Enzyme Regul. 50, 96-103 (2010).
7. Simon, J.A. & Lange, C.A. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat. Res. 647, 21-29 (2008).
8. Delhommeau, F. et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 360, 2289-2301 (2009).
9. Langemeijer, S.M. et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat. Genet. 41, 838-842 (2009).
10. Jones, A.V. et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat. Genet. 41, 446-449 (2009).
11. Mouthon, M.A. et al. Growth and differentiation of the human megakaryoblastic cell line (ELF-153): a model for early stages of megakaryocytopoiesis. Blood 84, 1085-1097 (1994).
12. Nakagawa, T. & Matozaki, S. The SKM-1 leukemic cell line established from a patient with progression to myelomonocytic leukemia in myelodysplastic syndrome (MDS)-contribution to better understanding of MDS. Leuk. Lymphoma 17, 335-339 (1995).
13. Dohner, K. et al. Molecular cytogenetic characterization of a critical region in bands 7q35-q36 commonly deleted in malignant myeloid disorders. Blood 92, 4031-4035 (1998).
14. Bracken, A.P. & Helin, K. Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat. Rev. Cancer 9, 773-784 (2009).
15. Cao, R. et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298, 1039-1043 (2002).
16. Czermin, B. et al. Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites. Cell 111, 185-196 (2002).
17. Muller, J. et al. Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell 111, 197-208 (2002).
18. Kuzmichev, A., Nishioka, K., Erdjument-Bromage, H., Tempst, P. & Reinberg, D. Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev. 16, 2893-2905 (2002).
19. Vire, E. et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439, 871-874 (2006).
20. Tiwari, V.K. et al. PcG proteins, DNA methylation, and gene repression by chromatin looping. PLoS Biol. 6, 2911-2927 (2008).
21. Kondo, Y. et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat. Genet. 40, 741-750 (2008).
22. Morin, R.D. et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42, 181-185 (2010).
23. Varambally, S. et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322, 1695-1699 (2008).
24. Karanikolas, B.D., Figueiredo, M.L. & Wu, L. Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line. Mol. Cancer Res. 7, 1456-1465 (2009).
25. Holland, D. et al. Activation of the enhancer of zeste homologue 2 gene by the human papillomavirus E7 oncoprotein. Cancer Res. 68, 9964-9972 (2008).
26. Van Haaften, G. et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat. Genet. 41, 521-523 (2009).
27. Bernstein, B.E. et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125, 315-326 (2006).
28. Cui, K. et al. Chromatin signatures in multipotent human hematopoietic stem cells indicate the fate of bivalent genes during differentiation. Cell Stem Cell 4, 80-93 (2009).
29. Kamminga, L.M. et al. The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood 107, 2170-2179 (2006).
30. Fiskus, W. et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 114, 2733-2743 (2009).
31. Yamamoto, G. et al. Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am. J. Hum. Genet. 81, 114-126 (2007).
32. Iafrate, A.J. et al. Detection of large-scale variation in the human genome. Nat. Genet. 36, 949-951 (2004).
33. White, H.E., Hall, V.J. & Cross, N.C.P. Methylation-sensitive high-resolution melting-curve analysis of the SNRPN gene as a diagnostic screen for Prader-Willi and Angelman syndromes. Clin. Chem. 53, 1960-1962 (2007).
34. Jones, A.V. et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood 107, 3339-3341 (2006).
35. Cross, N.C.P. et al. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia. 8, 186-189 (1994).
36. Beillard, E. et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)-a Europe against cancer program. Leukemia 17, 2474-2486 (2003).
37. Livak, K.J. & Schmittgen, T.D. Analysis of relative gene expression data using realtime quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402-408 (2001).
38. Margueron, R. et al. Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol. Cell 32, 503-518 (2008).
39. Shen, X. et al. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol. Cell 32, 491-502 (2008).